Abstract:Abstract Assessing quality of life (QoL) is crucial in managing patients with alopecia areata (AA), but the optimal health-related quality-of-life (HRQoL) measures remain debated. This uncertainty has been highlighted by recent clinical trials of Janus kinase inhibitors for severe AA, which employed various tools to evaluate the impact of AA and treatment effects on patient QoL. Measures used included generic scores [e.g. Hospital Anxiety and Depression Scale (HADS) and EuroQol (EQ)-5D-5L] and AA-specific scores (e.g. Alopecia Areata Symptom Impact Scale and Skindex-16-AA). Despite the well-recognized psychological impact of severe AA, EQ-5D-5L-based cost-effectiveness models failed to demonstrate significant improvement post-treatment. The current study aimed to evaluate the usefulness of QoL scores [Dermatology Life Quality Index (DLQI) and HADS] routinely collected from patients attending a specialist alopecia clinic. As there is no gold-standard QoL measure for alopecia, we analysed whether there was a correlation between DLQI and HADS, and with clinician-rated disease severity. The influence of psychiatric history and patient age was also assessed. Quantitative data were evaluated using SPSS (version 29.0.1.0; IBM, Armonk, NY, USA) for descriptive and parametric analyses. In total, 179 patients were assessed (17 male, 162 female; age 15–78 years). The results showed moderate positive correlations between DLQI and HADS-D (depression; P < 0.001), DLQI and HADS-A (anxiety; P < 0.001), and DLQI and total HADS (P < 0.001). DLQI correlated positively with clinician-rated disease severity (P = 0.003); however, no association was observed between HADS and clinician-rated disease severity scores. Patients with a pre-existing psychiatric history had higher DLQI (P = 0.03), HADS-D (P < 0.001) and HADS-A scores (P < 0.001). Patients with scarring alopecia tended to have lower DLQI scores, while patients with nonscarring alopecia had higher scores (P < 0.006). There was a statistically significant relationship between DLQI and patients’ ages, with younger patients more likely to have ‘moderate’ or ‘very large’ DLQI (P < 0.004). On the basis of these results, DLQI and HADS correlate moderately; however, only DLQI correlates with clinician-assessed disease severity. Patients with a psychiatric history and nonscarring alopecia tended to have higher scores, and younger patients tended to score more highly using DLQI. The impact of alopecia on patients is often severe; however, the best measure(s) of assessment is unclear. Although it has limitations, DLQI seems to be a reasonable QoL measure for patients with alopecia and correlates with clinician assessment of disease extent. However, further research is required to identify the most useful QoL tools for patients with alopecia, and disease registries will facilitate this work.

BH08 Evaluating quality-of-life measures for alopecia: a comparative analysis of Dermatology Life Quality Index and Hospital Anxiety and Depression Scale correlations with disease severity